CG Oncology (CGON) Total Non-Current Liabilities (2023 - 2026)

CG Oncology (CGON) has 4 years of Total Non-Current Liabilities data on file, last reported at $42.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $42.0 million; the trailing twelve-month figure through Mar 2026 stood at $42.0 million (changed N/A YoY), and the FY2025 full-year result was $37.2 million, up 73.9% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $42.0 million, up from $37.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $42.0 million in Q1 2026 and bottomed at $14.1 million in Q4 2023.
• The 4-year median for Total Non-Current Liabilities is $37.2 million (2025), against an average of $30.7 million.
• The widest annual swing landed in 2024, when Total Non-Current Liabilities soared 51.42%; it then jumped 73.9% in 2025.
• A 4-year view of Total Non-Current Liabilities shows it stood at $14.1 million in 2023, then surged by 51.42% to $21.4 million in 2024, then surged by 73.9% to $37.2 million in 2025, then increased by 12.84% to $42.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $42.0 million (Q1 2026), $37.2 million (Q4 2025), and $38.5 million (Q3 2025), per Business Quant data.

Peer Comparison